Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.

Inclusion criteria

• Females 18 years to 40 years of age Diagnosed as PCOS by the 2003 Rotterdam criteria
• Overweight/obesity (BMI≥24 kg/m2)
• No pregnant plan in recent 6 months
• Written consent for participation in the study

Exclusion criteria

• type 1 or type 2 diabetes mellitus
• Subjects have other endocrine diseases, such as adrenal hyperplasias or tumor, androgen-secreting tumors, Cushing's syndrome, thyroid diseases, and hyperprolactinemia
• Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Serious systemic disease or malignant tumor
• History of pancreatitis (chronic, acute or recurrent)
• Body weight change ≥10% at 3 months before treatment
• Used oral contraceptives or sex hormone drugs in the past 1 month
• Used oral glucocorticoids in the past 1 month
• Substance (alcohol or drug) abuse or dependence within 3 months
• Heavy smokers (smokers who smoke 20 or more cigarettes a day) or heavy drinkers (>10g/d)
• Subjects have a severe systemic disease, such as cardiovascular system, Renal impairment (eGFR<60ml/min/1.73m2)
• Increase of transaminases up to < 2.5 times of upper limit of normal value
• Have a history of thromboembolic disease or thrombotic tendency
• Subjects in pregnant or lactating or within 1 year after delivery
• Subjects have an allergic history to the drugs used in the study
• Subjects have participated in other clinical researches of medicine within 1 month prior to randomization
• Use of metformin, glucagon-like peptide -1 receptor agonists, or weight loss medications (prescription or OTC) within 30 days before screening